Aquapass’s fluid overload therapy system gains marketing approval in Israel
December 9, 2025
The approval is said to cover a range of clinical indications and supports use in both acute and chronic patients.
The approval is said to cover a range of clinical indications and supports use in both acute and chronic patients.
Resmed (NYSE: RMD)+
announced today that it received FDA clearance for its Smart Comfort personalized therapy offering.
Healthcare professionals can access the 1Bio AI-Acute toolbox via the company’s 1Bio platform.
Medtronic (NYSE: MDT)+
announced that the FDA approved expanded labeling for its deep brain stimulation (DBS) offering.
Cardiawave announced that it received CE mark approval for Valvosoft, its non-invasive therapeutic alternative for treating aortic stenosis (AS).
CAESAREA, Israel, Dec. 5, 2025 /PRNewswire/ — IceCure Medical Ltd. (NASDAQ: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced it received a Notice of Allowance for a patent from the China National Intellectual Property Administration for its invention titled “Cryogen Flow Control” which relates to its next-generation XSense™ cryoablation system and probes.
Insulet (Nasdaq: PODD)+
announced today that it received FDA 510(k) clearance for new enhancements to its Omnipod 5 system.
Atraverse Medical announced today that it received FDA clearance for its fully integrated Hotwire transseptal access system.
Boston Scientific (NYSE: BSX)+
announced recently that it received CE mark for its Farapoint pulsed field ablation (PFA) catheter.
The trial will enroll patients who are undergoing nerve management procedures for severe neuropathic pain.